The findings, published in the EMBO Journal, provide a possible explanation of the cause of Parkinson's disease and suggest that drugs designed to treat Parkinson's might work for TB too. LRRK2 inhibiting drugs are currently being developed to treat Parkinson's disease and by this means of this study, it can be repurposed to be a potential new TB therapy. ‘The most common genetic mutation in Parkinson's disease patients is in a gene called LRRK2 , which makes the LRRK2 protein overactive. Drugs that block LRRK2 are a promising new treatment for Parkinson's, with many pharmaceutical companies developing drugs to target LRRK2 and clinical trials underway.
But how overactive LRRK2 causes Parkinson's and why LRRK2 blockers work was a mystery. The biological causes of Parkinson's remain largely unknown, making it more difficult to develop and improve treatments. Discovering a mechanism that…
